offline
Healthcare | Biotechnology | USA
Sozusagen das gegenstück zu Bio-Path Holdings, IMGN heute 46% runter:
Immunogen Tanks After Ovarian Cancer Drug Study Fails to Meet Endpoint
Immunogen's cancer treatment candidate fails to meet the primary endpoint in a phase 3 trial.
...
"Even though FORWARD I did not meet its primary endpoint, I continue to be impressed with the efficacy and tolerability of mirvetuximab soravtansine in ovarian cancer patients, especially in the subset with high FRα expression," said Dr. Kathleen Moore, associate director of clinical research at the Stephenson Cancer Center at the University of Oklahoma. "I look forward to continuing to work with ImmunoGen to analyze the Phase 3 data and determine the most appropriate path to bringing mirvetuximab soravtansine to those patients who benefit most from it."
...
https://www.thestreet.com/investing/earn...yptr=yahoo
in phase 3 zu versagen ist natürlich schon heftig...
![[Bild: IMGNc1dl1745.png]](https://finviz.com/publish/030119/IMGNc1dl1745.png)
Sozusagen das gegenstück zu Bio-Path Holdings, IMGN heute 46% runter:
Immunogen Tanks After Ovarian Cancer Drug Study Fails to Meet Endpoint
Immunogen's cancer treatment candidate fails to meet the primary endpoint in a phase 3 trial.
...
"Even though FORWARD I did not meet its primary endpoint, I continue to be impressed with the efficacy and tolerability of mirvetuximab soravtansine in ovarian cancer patients, especially in the subset with high FRα expression," said Dr. Kathleen Moore, associate director of clinical research at the Stephenson Cancer Center at the University of Oklahoma. "I look forward to continuing to work with ImmunoGen to analyze the Phase 3 data and determine the most appropriate path to bringing mirvetuximab soravtansine to those patients who benefit most from it."
...
https://www.thestreet.com/investing/earn...yptr=yahoo
in phase 3 zu versagen ist natürlich schon heftig...
